Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2008

01-09-2008 | Endocrine Tumors

Prognostic Value of Lymph Node Yield and Metastatic Lymph Node Ratio in Medullary Thyroid Carcinoma

Authors: Maya D. Leggett, MD, Steven L. Chen, MD, MBA, Philip D. Schneider, MD, PhD, Steve R. Martinez, MD

Published in: Annals of Surgical Oncology | Issue 9/2008

Login to get access

Abstract

Introduction

Lymphadenectomy and thyroidectomy is standard treatment for medullary thyroid carcinoma (MTC), but the prognostic importance of the number of lymph nodes removed (lymph node yield, LNY) and the proportion of metastatic lymph nodes resected (metastatic lymph node ratio, MLNR) is unknown. We hypothesized that MTC survival is influenced by LNY and MLNR.

Methods

Patients (N = 534) who underwent thyroidectomy with lymphadenectomy for MTC between 1988 and 2004 were identified in the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan–Meier method was used for univariate comparisons of survival for LNY and MLNR with a maximum follow-up of 12 years. Cox regression models adjusted for age, sex, extent of disease, tumor size, nodal status, LNY, and MLNR.

Results

By univariate analysis, increasing LNY was associated with improved survival in all patients (P < 0.002) and node-positive patients (P < 0.001). In a multivariate analysis using LNY and MLNR as categorical variables, significant factors influencing survival included: age (P < 0.001), tumor size (P < 0.001), LNY (P = 0.007), and MLNR (P < 0.02); in node-negative patients: age (P = 0.002); in node-positive patients: age (P < 0.001), tumor size (P < 0.001), and LNY (P = 0.001). Using LNY and MLNR as continuous variables, significant factors influencing survival included: age (P < 0.001), tumor size (P < 0.001), and MLNR (P = 0.01); in node-negative patients: age (P < 0.001); in node-positive patients: age (P < 0.001) and tumor size (P < 0.001).

Conclusion

In patients undergoing thyroidectomy and lymphadenectomy for MTC, LNY and MLNR predict poorer survival, but their impact on survival was limited to node-positive patients and was otherwise dominated by the effects of age and extent of disease.
Literature
1.
go back to reference Grozinsky-Glasberg S, Benbassat CA, et al. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 2007; 17:549–56.PubMedCrossRef Grozinsky-Glasberg S, Benbassat CA, et al. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 2007; 17:549–56.PubMedCrossRef
2.
go back to reference Gulben K, Berberoglu U, Boyabatli M. Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg 2006; 30:84–90.PubMedCrossRef Gulben K, Berberoglu U, Boyabatli M. Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg 2006; 30:84–90.PubMedCrossRef
3.
go back to reference Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 2003; 128:115–23.PubMedCrossRef Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 2003; 128:115–23.PubMedCrossRef
4.
go back to reference Kebebew E, Greenspan FS, Clark OH, et al. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 2005; 200:890–6.PubMedCrossRef Kebebew E, Greenspan FS, Clark OH, et al. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 2005; 200:890–6.PubMedCrossRef
5.
go back to reference Leboulleux S, Travagli JP, Caillou B, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer 2002; 94:44–50.PubMedCrossRef Leboulleux S, Travagli JP, Caillou B, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer 2002; 94:44–50.PubMedCrossRef
6.
go back to reference Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305–10.PubMedCrossRef Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305–10.PubMedCrossRef
7.
go back to reference Esik O, Tusnady G, Tron L, et al. Markov model-based estimation of individual survival probability for medullary thyroid cancer patients. Pathol Oncol Res 2002; 8:93–104.PubMedCrossRef Esik O, Tusnady G, Tron L, et al. Markov model-based estimation of individual survival probability for medullary thyroid cancer patients. Pathol Oncol Res 2002; 8:93–104.PubMedCrossRef
8.
go back to reference Greenblatt DY, Elson D, Mack E, et al. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg 2007; 30:108–12.PubMed Greenblatt DY, Elson D, Mack E, et al. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg 2007; 30:108–12.PubMed
9.
go back to reference Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000; 89:202–17.PubMedCrossRef Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000; 89:202–17.PubMedCrossRef
10.
go back to reference Brumsen C, Haak HR, Goslings BM, et al. Should patients with medullary thyroid carcinoma undergo extensive lymph node (re)operation to improve long-term survival? Henry Ford Hosp Med J 1992; 40:271–5.PubMed Brumsen C, Haak HR, Goslings BM, et al. Should patients with medullary thyroid carcinoma undergo extensive lymph node (re)operation to improve long-term survival? Henry Ford Hosp Med J 1992; 40:271–5.PubMed
11.
go back to reference Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001; 130:1044–9.PubMedCrossRef Weber T, Schilling T, Frank-Raue K, et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001; 130:1044–9.PubMedCrossRef
12.
go back to reference Oskam IM, Hoebers F, Balm AJ, et al. Neck management in medullary thyroid carcinoma. Eur J Surg Oncol 2008; 34:71–6.PubMed Oskam IM, Hoebers F, Balm AJ, et al. Neck management in medullary thyroid carcinoma. Eur J Surg Oncol 2008; 34:71–6.PubMed
13.
go back to reference Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999; 229:880–7; discussion 7–8.PubMedCrossRef Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999; 229:880–7; discussion 7–8.PubMedCrossRef
14.
go back to reference Moley JF, Fialkowski EA. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 2007; 31:946–56.PubMedCrossRef Moley JF, Fialkowski EA. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 2007; 31:946–56.PubMedCrossRef
15.
go back to reference Green FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 6th edn. 2002:77–88 Green FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 6th edn. 2002:77–88
16.
go back to reference Ellenhorn JD, Shah JP, Brennan MF. Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 1993; 114:1078–81; discussion 81–2.PubMed Ellenhorn JD, Shah JP, Brennan MF. Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 1993; 114:1078–81; discussion 81–2.PubMed
17.
go back to reference Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999; 230:697–707.PubMedCrossRef Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999; 230:697–707.PubMedCrossRef
18.
go back to reference Kallinowski F, Buhr HJ, Meybier H, et al. Medullary carcinoma of the thyroid–therapeutic strategy derived from fifteen years of experience. Surgery 1993; 114:491–6.PubMed Kallinowski F, Buhr HJ, Meybier H, et al. Medullary carcinoma of the thyroid–therapeutic strategy derived from fifteen years of experience. Surgery 1993; 114:491–6.PubMed
19.
go back to reference Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88:1139–48.PubMedCrossRef Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88:1139–48.PubMedCrossRef
20.
go back to reference Machens A, Gimm O, Ukkat J, et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 2000; 88:1909–15.PubMedCrossRef Machens A, Gimm O, Ukkat J, et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 2000; 88:1909–15.PubMedCrossRef
21.
go back to reference Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. Langenbecks Arch Surg 1998; 383:334–6.PubMedCrossRef Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. Langenbecks Arch Surg 1998; 383:334–6.PubMedCrossRef
22.
go back to reference van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990; 212:395–400; discussion 400–1.PubMedCrossRef van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990; 212:395–400; discussion 400–1.PubMedCrossRef
23.
go back to reference Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007; 33:493–7.PubMedCrossRef Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007; 33:493–7.PubMedCrossRef
24.
go back to reference Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994; 24:112–21.PubMedCrossRef Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994; 24:112–21.PubMedCrossRef
25.
go back to reference Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery 2006; 139:28–32.PubMedCrossRef Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery 2006; 139:28–32.PubMedCrossRef
26.
go back to reference American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006; 12:63–102 American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006; 12:63–102
27.
go back to reference Fialkowski E, Debenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 2008; 32:754–65.PubMedCrossRef Fialkowski E, Debenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 2008; 32:754–65.PubMedCrossRef
28.
go back to reference Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 1998; 83:2638–48.PubMedCrossRef Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 1998; 83:2638–48.PubMedCrossRef
Metadata
Title
Prognostic Value of Lymph Node Yield and Metastatic Lymph Node Ratio in Medullary Thyroid Carcinoma
Authors
Maya D. Leggett, MD
Steven L. Chen, MD, MBA
Philip D. Schneider, MD, PhD
Steve R. Martinez, MD
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 9/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0022-z

Other articles of this Issue 9/2008

Annals of Surgical Oncology 9/2008 Go to the issue